Search results for "Dosing interval"

showing 2 items of 2 documents

Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varice…

2016

Background Varicella is a highly infectious disease with a significant public health and economic burden, which can be prevented with childhood routine varicella vaccination. Vaccination strategies differ by country. Some factors are known to play an important role (number of doses, coverage, dosing interval, efficacy and catch-up programmes), however, their relative impact on the reduction of varicella in the population remains unclear. This paper aims to help policy makers prioritise the critical factors to achieve the most successful vaccination programme with the available budget. Methods Scenarios assessed the impact of different vaccination strategies on reduction of varicella disease…

Budgets0301 basic medicineMalePediatricsNational Health ProgramsNational Health ProgramDiseaseVaricella0302 clinical medicineChickenpoxEpidemiology030212 general & internal medicineChildChickenpox Vaccineeducation.field_of_studyChickenpoxlcsh:Public aspects of medicineImmunization ProgramVaccinationvirus diseasesCoverage; Dosing interval; Efficacy; Routine varicella vaccination impact; VaricellaVaccinationItalyBudgetDosing intervalFemalePublic HealthResearch ArticleHumanmedicine.medical_specialtyCoverageAdolescentEfficacy030106 microbiologyPopulationSocio-culturaleVaccines AttenuatedMass VaccinationRoutine varicella vaccination impactChickenpox Vaccine03 medical and health sciencesCoverage; Dosing interval; Efficacy; Routine varicella vaccination impact; Varicella; Public Health Environmental and Occupational HealthmedicineHumansDosingeducationImmunization Programsbusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthlcsh:RA1-1270Models Theoreticalmedicine.diseaseVaccine efficacybusinessBMC Public Health
researchProduct

Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Phar…

2011

The renin-angiotensin-aldosterone system (RAAS) plays a dominant role in the pathophysiology of hypertension, diabetes mellitus, chronic kidney disease and chronic heart failure. Therefore, drugs that block key components of the RAAS such as ACE inhibitors (ACEI) and angiotensin receptor blockers (ARBs) have gained wide clinical use for these indications. Despite progress, the morbidity and mortality of patients treated with ACEI or ARBs remain high. Aliskiren (Tekturna, Rasilez) is the first orally active inhibitor of renin approved for clinical use as an antihypertensive agent. The development program has established that at the licensed doses of 150 mg and 300 mg. Aliskiren is effective …

DrugRamiprilbusiness.industrymedia_common.quotation_subjectlcsh:RPharmaceutical ScienceCorrectionlcsh:Medicinelcsh:RS1-441AliskirenPharmacologylcsh:Pharmacy and materia medicachemistry.chemical_compoundIrbesartanAliskiren 300 MGn/achemistryDrug DiscoverymedicineMolecular MedicineDosing intervalbusinessmedia_commonmedicine.drugPharmaceuticals
researchProduct